Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results
Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled trial.
